Pheromone Sciences Corp. Receives Final Clearance on Prospectus

Apr 12, 2001, 01:00 ET from Pheromone Sciences Corp.

    TORONTO, April 12 /PRNewswire/ - Pheromone Sciences Corp. (CDNX:PHS)
 today announced that it has received final clearance of its prospectus
 relating to the $2.0 million special warrant private placement completed in
 late February.
     Under the terms of the placement each special warrant of the Company will
 be converted, at no additional consideration, into one common share and one-
 half of a warrant. Each whole warrant will entitle the holder to purchase one
 common share of the Company at an exercise price of $1.25 per share until
 February 23, 2002.
     Pheromone Sciences Corp. is a biotechnology and medical diagnostics
 device research and development company that focuses on commercializing
 technologies in the field of human reproduction and sexuality.
 
     Statements contained in this press release, including those pertaining to
 scientific and clinical research, commercialization plans, strategic
 alliances, and intellectual property protection, other than statements of
 historical fact, are forward-looking statements subject to a number of
 uncertainties that could cause actual results to differ materially from
 statements made. The Canadian Venture Exchange has not reviewed and does not
 accept responsibility for the adequacy or the contents of this news release.
 
 

SOURCE Pheromone Sciences Corp.
    TORONTO, April 12 /PRNewswire/ - Pheromone Sciences Corp. (CDNX:PHS)
 today announced that it has received final clearance of its prospectus
 relating to the $2.0 million special warrant private placement completed in
 late February.
     Under the terms of the placement each special warrant of the Company will
 be converted, at no additional consideration, into one common share and one-
 half of a warrant. Each whole warrant will entitle the holder to purchase one
 common share of the Company at an exercise price of $1.25 per share until
 February 23, 2002.
     Pheromone Sciences Corp. is a biotechnology and medical diagnostics
 device research and development company that focuses on commercializing
 technologies in the field of human reproduction and sexuality.
 
     Statements contained in this press release, including those pertaining to
 scientific and clinical research, commercialization plans, strategic
 alliances, and intellectual property protection, other than statements of
 historical fact, are forward-looking statements subject to a number of
 uncertainties that could cause actual results to differ materially from
 statements made. The Canadian Venture Exchange has not reviewed and does not
 accept responsibility for the adequacy or the contents of this news release.
 
 SOURCE Pheromone Sciences Corp.